JAM3 and neoplasm: In conclusion, we suggest that JAM-C is a potential therapeutic target to control tumor angiogenesis, since an antibody-based approach could inhibit the angiogenic functions of both mature endothelial cells and, in particular, as shown here, endothelial progenitors.